Your Annual Physical Is Missing These Eight Tests.

The standard annual physical measures a narrow slice of cardiovascular biology. It was not designed as a full cardiovascular risk screen. It was designed as a practical clinical encounter under time pressure, measuring what is fastest, most widely reimbursed, and easiest to defend in a seven-minute appointment.

What that system gives you: a blood pressure reading, a weight, and a lipid panel that has not changed substantially since the 1980s. Total cholesterol, LDL, HDL, triglycerides, and a fasting glucose. These are the floor of cardiovascular measurement. They catch some things reliably. They miss others completely.

Here are the eight tests most likely to catch what the standard panel cannot.

The Mechanism

The standard panel was built around the tools of its era. LDL cholesterol became the primary lipid target after the Framingham Heart Study data of the 1960s and 1970s established that cholesterol mass correlated with cardiovascular risk. Fasting glucose became the metabolic reference point because it was measurable, reproducible, and a known precursor to diabetes. These are not bad measurements. They are incomplete ones.

The problem is that both LDL and fasting glucose are late-stage detectors in the populations where cardiovascular disease is most preventable.

LDL measures the cholesterol content inside low-density lipoprotein particles, not the number of particles. In a man with a large waist, elevated triglycerides, and low HDL, the liver produces small, dense, triglyceride-rich particles. These particles carry less cholesterol per unit volume than large, buoyant LDL particles. The result: high particle count, low cholesterol mass, an LDL that reports acceptable, and an arterial wall accumulating burden. The mathematical reason is straightforward. If you carry 1,600 small particles rather than 900 large ones, the total cholesterol content per particle is lower, so LDL comes out looking normal even though the atherogenic load is substantially higher. ApoB measures the particle count directly, because every atherogenic particle carries exactly one ApoB molecule on its surface.

Fasting glucose catches diabetes after the pancreas has been compensating for, in many cases, a decade. The sequence: peripheral insulin resistance develops first, cells in muscle and liver become less responsive to insulin’s signal. The beta cells detect this and produce more insulin to compensate. Fasting glucose stays normal, sometimes for years, because the compensation is working. The standard metabolic panel reports normal. Fasting insulin, if measured, reveals a number well above the threshold of clinical concern. This is the detection gap.

The reimbursement structure reinforces both gaps. The standard lipid panel costs a fraction of what a complete cardiometabolic panel costs. The annual physical is a time-limited encounter. Physicians ordering outside the standard panel need to justify each addition, and in a seven-minute appointment, that justification rarely happens unless the patient asks.

What the Evidence Shows

ApoB. The 2019 European Society of Cardiology guidelines, after reviewing prospective cohort data, Mendelian randomization analyses, and randomized trial subgroups, concluded that ApoB is a more accurate measure of cardiovascular risk than LDL cholesterol and recommended it as the primary lipid target in patients at elevated risk. 5 / Solid The JAMA Cardiology analysis of the Multi-Ethnic Study of Atherosclerosis (MESA), published in 2022 across 6,674 participants, found ApoB had more consistent associations with cardiovascular events than LDL, and the advantage was most pronounced in the metabolic syndrome phenotype, exactly the patient whose LDL is most likely to mislead. The man with ApoB-LDL discordance, acceptable LDL but elevated ApoB, carries a cardiovascular risk that his standard panel actively conceals.

Fasting insulin. The Insulin Resistance Atherosclerosis Study (IRAS), a multicenter prospective cohort, found that insulin resistance measured by insulin sensitivity testing was independently associated with carotid intima-media thickness progression, a validated marker of subclinical atherosclerosis, after adjustment for traditional cardiovascular risk factors (Wagenknecht et al., Arteriosclerosis, Thrombosis, and Vascular Biology, 1997). 4 / Promising The METSIM study, following Finnish men prospectively, found that fasting insulin independently predicted cardiovascular events after adjustment for glucose, lipids, and blood pressure, confirming that the insulin resistance state itself, not only its glycemic consequence, carries independent cardiovascular risk.

Elevated circulating insulin has four direct cardiovascular effects. First, it promotes sodium retention through stimulation of renal collecting duct channels, producing a volume-expanded state that elevates blood pressure independent of dietary sodium. Second, it drives hepatic VLDL production, which produces small, dense, triglyceride-depleted LDL particles after lipoprotein lipase processing, elevating ApoB particle count while keeping LDL-C acceptable. Third, in insulin-resistant individuals, the PI3K pathway that drives beneficial endothelial nitric oxide production is selectively impaired, while the pro-inflammatory and vasoconstrictive effects of insulin are preserved, producing endothelial dysfunction. Fourth, it promotes visceral fat accumulation preferentially, and visceral fat returns free fatty acids to the portal circulation, releases inflammatory cytokines, and amplifies the resistance that produced it. A fasting insulin above 10 uIU/mL with a normal glucose indicates this state is active.

Coronary artery calcium (CAC) score. This is not a blood test. It is a CT scan, twelve minutes, no contrast, $100 to $150 out of pocket at most US imaging centers. The MESA trial, published in the New England Journal of Medicine (Detrano et al., 2008), enrolled 6,814 adults without known cardiovascular disease and followed them for a median of approximately 10 years. A CAC score of 1 to 10 carried a hazard ratio of 3.66 for coronary events compared to a score of zero, after full adjustment for traditional risk factors. A score above 300 carried event rates comparable to patients with established cardiovascular disease. A score of zero in a man aged 40 to 55 with no major risk features corresponds to a 10-year major cardiovascular event risk below 1 percent. 5 / Solid

The clinical utility is in reclassification. The intermediate-risk man, the one sitting on the borderline of a statin conversation, has a genuinely uncertain risk calculation. A CAC of zero appropriately defers initiation in many of these cases. A CAC of 280 resolves the uncertainty in the other direction. That is an anatomical finding, not a statistical inference.

High-sensitivity CRP (hsCRP). Standard CRP assays are calibrated for acute illness, the 10 to 100 mg/L range. They are insensitive to the 1 to 5 mg/L range where cardiovascular risk lives. High-sensitivity CRP measures the same protein by a more sensitive assay. For cardiovascular risk assessment, only hsCRP is clinically meaningful. The JUPITER trial (Ridker et al., New England Journal of Medicine, 2008) enrolled 17,802 men and women with LDL below 130 mg/dL but hsCRP at or above 2.0 mg/L. Randomized to rosuvastatin versus placebo, the treatment group showed a 44 percent reduction in major cardiovascular events and a 37 percent reduction in hsCRP, independent of LDL lowering. The trial was stopped early for overwhelming benefit. 5 / Solid

The clinical implication: a man with an LDL of 110 and an hsCRP of 3.2 mg/L is not fine because his cholesterol is acceptable. His inflammatory burden carries independent cardiovascular risk that his lipid panel does not capture. An hsCRP above 3.0 mg/L is associated with approximately double the cardiovascular mortality of an hsCRP below 1.0 mg/L, independent of LDL.

Lipoprotein(a). Lp(a) is a genetic variant of LDL in which the ApoB-100 protein is covalently bonded to a second protein called apolipoprotein(a). Apolipoprotein(a) has a structural similarity to plasminogen, the enzyme that dissolves blood clots. This homology means Lp(a) competes with plasminogen for fibrin binding sites, impairing clot dissolution and making Lp(a) both atherogenic and prothrombotic through a mechanism that is structurally distinct from LDL. 5 / Solid

Lp(a) concentration is 80 to 90 percent genetically determined. It is not substantially altered by diet, exercise, or standard statin therapy. The Copenhagen City Heart Study and its meta-analyses established that Lp(a) above 50 mg/dL (approximately 125 nmol/L in mass-equivalent terms) is associated with approximately double the cardiovascular risk independent of all other factors, and that approximately 1 in 5 people carries a level in this range. Current European and American cardiology guidelines recommend measuring Lp(a) at least once in every adult’s lifetime. It is not on the standard panel. It only needs to be measured once.

Free testosterone. Total testosterone appears on many standard panels. Free testosterone does not. Total testosterone includes the fraction bound to sex hormone-binding globulin (SHBG), which is biologically inactive: the SHBG-bound molecule cannot bind to androgen receptors or exert physiological effect. Free testosterone is the unbound, biologically active fraction. A man can have a total testosterone in the mid-normal range while SHBG is elevated for any of several reasons, including age, obesity, thyroid dysfunction, or alcohol use, and experience every clinical manifestation of hypogonadism because his free fraction is low. The symptom burden is driven by the active fraction, not the total number.

The cardiovascular connection is indirect but real. Low free testosterone is associated with insulin resistance, visceral adiposity, elevated inflammatory markers, and impaired endothelial function across multiple cross-sectional and prospective studies. The mechanism is bidirectional: low testosterone promotes metabolic dysfunction, and metabolic dysfunction suppresses testosterone. Measuring only total T misses the men in the low-free, normal-total category, who may be symptomatic and at elevated metabolic risk.

24-hour ambulatory blood pressure. A single clinic blood pressure reading captures one moment in one context. It does not show whether blood pressure rises at night, falls appropriately during sleep, surges in the morning, or is chronically elevated outside the clinical environment. A 24-hour ambulatory monitor captures all of these.

The nocturnal dip, a normal 10 to 20 percent reduction in blood pressure during sleep, is independently predictive of cardiovascular outcomes. The Dolan et al. analysis, published in the Journal of Hypertension (2005), found that nocturnal systolic blood pressure was a stronger predictor of cardiovascular mortality than daytime systolic blood pressure, and that non-dippers, men whose blood pressure does not fall appropriately during sleep, carried significantly higher cardiovascular event rates than dippers with equivalent daytime readings. 4 / Promising Non-dipping is observed in approximately 25 percent of hypertensive patients and is associated with target organ damage disproportionate to the daytime readings.

The morning surge, the rapid rise in blood pressure in the first 1 to 2 hours after waking, corresponds to the peak period for cardiovascular events. Myocardial infarction and stroke are most frequent in the morning hours, and morning surge magnitude is one proposed mechanism. Ambulatory monitoring captures this pattern. A single clinic reading taken mid-morning after the surge has resolved does not.

Masked hypertension, elevated out-of-office blood pressure with a normal clinic reading, affects approximately 15 to 20 percent of men told their blood pressure is normal. It carries cardiovascular mortality rates comparable to sustained hypertension. Muntner et al., published in Circulation in 2019, confirmed this finding in a large US population sample. Ambulatory monitoring identifies it. A once-yearly clinic reading does not. 5 / Solid

HbA1c. Hemoglobin A1c measures the average blood glucose over the preceding two to three months by assessing the proportion of hemoglobin with glucose attached. It is not affected by what the patient had for dinner the night before the test, whether he fasted longer than usual, or whether he was dehydrated. A fasting glucose taken on a morning when a man ate lightly and exercised the day before can appear entirely normal while HbA1c captures three months of glucoregulatory reality.

The prediabetes range, an HbA1c of 5.7 to 6.4 percent, corresponds to a state of impaired fasting glucose and glucose tolerance that carries independent cardiovascular risk before the diabetes threshold is crossed. The relationship between glycemic dysregulation and cardiovascular disease does not begin at the diagnostic threshold for diabetes. Evidence from the Emerging Risk Factors Collaboration (Sarwar et al., Lancet, 2010, over 300,000 participants across 73 prospective studies) established that HbA1c in the prediabetes range is associated with elevated cardiovascular event rates independent of other risk factors. 5 / Solid

HbA1c is on many standard panels but not all. When it is present, it adds meaningful information. When only fasting glucose is ordered, an episodic pattern of postprandial hyperglycemia that does not meet the fasting threshold can go undetected for years.

What to Do This Week

1. At your next visit, ask specifically for ApoB and fasting insulin. The exact language: “Can we add ApoB and fasting insulin to my labs?” Both are commonly covered by insurance as part of a cardiovascular or metabolic workup. Both are available at standard labs. Both require a single blood draw. You do not need a referral and you do not need a specialist to order them.

2. Ask whether your Lp(a) has ever been measured. If you have never had it checked, ask: “Has my Lp(a) ever been ordered?” If no, ask that it be added. It only needs to be measured once. It does not change with lifestyle. Knowing it changes how aggressively every other risk factor needs to be managed.

3. Ask about a coronary artery calcium scan if you are 40 to 60 and any of the following apply: you have borderline risk factors, you are uncertain about whether to start preventive therapy, or you have a first-degree relative who had a heart attack before 60. The specific language: “Is a coronary artery calcium scan appropriate for me given my age and risk factors?” This is a $100 to $150 out-of-pocket test at most US imaging centers. It is twelve minutes. A zero score is a powerful finding. A non-zero score changes what happens next.

4. If your blood pressure is borderline or if you have been told it looks fine in the office but you feel symptoms, ask about 24-hour ambulatory blood pressure monitoring. The specific language: “Can we do a 24-hour blood pressure monitor to see my full pattern, including overnight?” This distinguishes white-coat hypertension from masked hypertension, captures the nocturnal dip, and changes the management conversation in a way that a single clinic reading cannot.

5. Ask for hsCRP and make sure it is high-sensitivity CRP, not standard CRP. Standard CRP is insensitive to the range where cardiovascular risk lives. If you have borderline lipids, a history of inflammatory conditions, or metabolic syndrome features, hsCRP adds meaningful information. The exact language: “Can we add high-sensitivity CRP to my labs?” It is inexpensive and changes the risk conversation if the result is above 2 mg/L.

None of these tests require a concierge practice, a functional medicine clinic, or a specialized center. They require a physician willing to order them and a patient willing to ask. The gap between the standard panel and a complete cardiometabolic picture is closed, in most cases, by one direct conversation at an annual visit that would otherwise end with “everything looks normal.”

What the system gives you by default is not negligent. It is incomplete. The eight tests above represent the gap between what the system offers and what the evidence supports. You are the one who knows whether you have had them.